WHAT IS CLAIMED IS:

1. ~~A method for treating T2DM comprising administering to a human in need thereof~~ Use of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof in the manufacture of a pharmaceutical composition for the treatment of T2DM, wherein:

the pharmaceutical composition is in an oral dosage form; and

the pharmaceutical composition ~~comprises 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof~~is to be administered to a human in need thereof~~.~~

2. The ~~method~~ use of claim 1, wherein the pharmaceutical composition is in an immediate-release solid dosage form.

3. The ~~method~~ use of claim 1 or 2, wherein the pharmaceutical composition is in an immediate-release tablet dosage form.

4. The ~~method~~ use of any one of claims 1 to 3, wherein the pharmaceutical composition comprises 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof in an amount equivalent to about 10 mg to about 140 mg of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid.

5. The ~~method~~ use of any one of claims 1 to 3, wherein the 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid or pharmaceutically salt thereof in the pharmaceutical composition is tris salt of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid.

6 The ~~method~~ use of any one of claims 1 to 5, wherein the pharmaceutical composition is to be administered twice daily.

7. The ~~method~~ use of claim 6, wherein the two daily administrations are separated by at least about 8 hours.

8. The ~~method~~ use of any one of claims 1 to 7, wherein the treating D2TM comprises improving glycemic control.

9. ~~A method for weight management control or for treating obesity or overweight comprising administering to a human in need thereof~~ Use of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof in the manufacture of a pharmaceutical composition for weight management control or for the treatment of obesity or overweight, wherein:

the pharmaceutical composition is in a solid oral dosage form; and

the pharmaceutical composition is to be administered to a human in need thereof~~comprises 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof~~.

10. The ~~method~~ use of claim 9, wherein the pharmaceutical composition comprises 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof in an amount equivalent to about 10 mg to about 140 mg of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid.

11. The ~~method~~ use of claim 9 or 10, wherein the pharmaceutical composition is to be administered twice daily.

12. The ~~method~~ use of claim 11, wherein the two daily administrations are separated by at least about 8 hours.

13. An immediate-release oral pharmaceutical composition comprising 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof.

14. An immediate-release oral pharmaceutical composition comprising:

2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof;

a filler;

a disintegrant; and

a lubricant.

15. The pharmaceutical composition of claim 14 wherein:

the 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid or a pharmaceutically acceptable salt thereof is tris salt of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid;

the filler comprises microcrystalline cellulose, lactose, or a combination thereof;
the disintegrant is sodium starch glycolate; and
the lubricant is magnesium stearate or sodium stearyl fumarate.

16. The pharmaceutical composition of claim 14 wherein:
the 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid or a pharmaceutically acceptable salt thereof is tris salt of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid;
the filler comprises microcrystalline cellulose, lactose, or a combination thereof;
the disintegrant is crospovidone; and
the lubricant is magnesium stearate or sodium stearyl fumarate.

17. The pharmaceutical composition of claim 14 or 15, wherein:
the 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid or a pharmaceutically acceptable salt thereof comprises about 1.0% to about 35.0% by weight;
the filler comprises about 60% to about 95% by weight;
the disintegrant comprises about 1.0% to about 5.0% by weight; and
lubricant comprises about 0.2% to about 2.5% by weight.

18. The pharmaceutical composition of any one of claims 13 to 17, wherein the composition comprise tris salt of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid in an amount equivalent to about 10 mg to about 120 mg of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid.

19. The pharmaceutical composition of any one of claims 13 to 17 for use in ~~treating~~ the treatment of T2DM or in weight management control.

20. The pharmaceutical composition of claim 19 wherein the composition is used by twice daily administration.